🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Travere Therapeutics Inc (TVTX)

NASDAQ
Currency in USD
18.56
-0.19(-1.01%)
Closed
After Hours
18.00-0.56(-3.02%)
TVTX Scorecard
Full Analysis
Quickly burning through cash
Fair Value
Day's Range
18.5019.51
52 wk Range
5.1220.33
Key Statistics
Edit
Prev. Close
18.56
Open
19
Day's Range
18.5-19.51
52 wk Range
5.12-20.33
Volume
1,255,791
Average Volume (3m)
1,848,154
1-Year Change
204.76%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TVTX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
26.38
Upside
+42.13%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period
Show more

Travere Therapeutics Inc Company Profile

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company’s clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health’s National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

InvestingPro Research for Travere Therapeutics Inc


Filspari's Triumph
Explore Travere Therapeutics' market resurgence following Filspari's full FDA approval for IgA nephropathy, doubling its addressable market and boosting growth prospects
Financial Outlook
Analyst projections show revenue rebounding to $230.5M in FY 2024, with EPS estimates ranging from -$3.05 to -$0.53, reflecting ongoing challenges and potential
Competitive Edge
Delve into Travere's strengthened position in the rare kidney disease market, with Filspari poised to become a standard of care amid evolving treatment guidelines
Future Catalysts
Learn about Travere's growth drivers, including REMS modifications and new indications for Filspari, with analyst price targets ranging from $12 to $20
Read full SWOT analysis

Compare TVTX to Peers and Sector

Metrics to compare
TVTX
Peers
Sector
Relationship
P/E Ratio
−4.2x−2.8x−0.7x
PEG Ratio
0.020.010.00
Price/Book
−47.6x2.1x2.6x
Price / LTM Sales
7.1x7.0x3.2x
Upside (Analyst Target)
30.7%118.2%47.0%
Fair Value Upside
Unlock4.5%8.3%Unlock

FAQ

What Is the Travere Therapeutics (TVTX) Stock Price Today?

The Travere Therapeutics stock price today is 18.56

What Stock Exchange Does Travere Therapeutics Trade On?

Travere Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Travere Therapeutics?

The stock symbol for Travere Therapeutics is "TVTX."

What Is the Travere Therapeutics Market Cap?

As of today, Travere Therapeutics market cap is 1.45B.

What is Travere Therapeutics Earnings Per Share?

The Travere Therapeutics EPS is -4.55.

What Is the Next Travere Therapeutics Earnings Date?

Travere Therapeutics will release its next earnings report on 02 Mar 2025.

From a Technical Analysis Perspective, Is TVTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.